Michael Diem, MBA '05
Posted 5.10.16Diem was recently appointed Senior Vice President of Business and Corporate Development at Medgenics, Inc.
PHILADELPHIA, PA--(Marketwired - May 3, 2016) -Medgenics, Inc. (NYSE MKT: MDGN) today announced the appointment of Michael Diem, MD as Senior Vice President of Corporate and Business Development. Dr. Diem will be a key member of the Medgenics leadership team, heading all business and corporate development activities. Mike was recently with AstraZeneca as the Head of Corporate Strategy and Corporate Development, where he was responsible globally for corporate strategy, corporate development and MedImmune Ventures. Prior to joining AstraZeneca, Mike was the Head of Business Development for GlaxoSmithKline (GSK) Rare Diseases where he was responsible for partnerships, licensing and mergers and acquisitions (M&A). Earlier in his career at GSK, Mike was a partner in its corporate venture capital firm, SR One, Limited where he was responsible for many of the firm's investments and served on the boards of numerous companies. Prior to GSK, Mike was an associate at Frantz Medical Ventures and practiced medicine for 6 years. He holds a BA in biological sciences from Rutgers University, an MD from the Rutgers-Robert Wood Johnson Medical School, an MBA from the Weatherhead School of Management at Case Western Reserve University, completed his medical training at Duke University Medical Center and is an alumnus of the Kauffman Fellows Program.
"We are very pleased to announce the appointment of Mike to our team," said Mike Cola, Chief Executive Officer of Medgenics. "Mike brings tremendous experience resulting from multiple strategic corporate development roles to Medgenics, and he will contribute significantly to our future growth as a company."